Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological respon...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/9/e005160.full |
| _version_ | 1797669462025961472 |
|---|---|
| author | Hao Long Si Chen Hui Yu Wen-Yu Zhai Ze-Rui Zhao Yao-Bin Lin Yi-Zhi Wang |
| author_facet | Hao Long Si Chen Hui Yu Wen-Yu Zhai Ze-Rui Zhao Yao-Bin Lin Yi-Zhi Wang |
| author_sort | Hao Long |
| collection | DOAJ |
| description | The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological response of PT and nodal downstaging using a pooled analysis to assess the effect of neoadjuvant immunotherapy on LNs. Original articles reporting the tumor major pathological response (ypT(MPR)), pathological complete response (ypT0) and nodal downstaging following neoadjuvant immunotherapy in NSCLC were retrieved. The OR and 95% CI were calculated by Review Manager V.5.3. Subgroup analysis was performed according to the neoadjuvant therapy regimen used. A total of 209 patients from 6 studies were included in this analysis. The frequency of nodal downstaging was comparable to that of ypT(MPR) (OR 1.31; 95% CI 0.84 to 2.05; p=0.24). Interestingly, ypN0 was observed more frequently than ypT0 (OR 3.26; 95% CI 2.06 to 5.16; p<0.0001). However, this difference was not observed in the subgroup of cN2 patients who underwent immune checkpoint inhibitor monotherapy (OR 1.58; 95% CI 0.56 to 4.48; p=0.39). Neoadjuvant immunotherapy results in satisfactory response in metastatic LN. Patients had a high probability of node clearance when ypT0 was confirmed, especially in patients treated with immunochemotherapy. |
| first_indexed | 2024-03-11T20:44:44Z |
| format | Article |
| id | doaj.art-c0c83f16f6a14fd0a60f093df5ef23d2 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T20:44:44Z |
| publishDate | 2022-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-c0c83f16f6a14fd0a60f093df5ef23d22023-10-01T18:55:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-09-0110910.1136/jitc-2022-005160Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysisHao Long0Si Chen1Hui Yu2Wen-Yu Zhai3Ze-Rui Zhao4Yao-Bin Lin5Yi-Zhi Wang6Lung Cancer Research Center, Sun Yat-Sen University, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaDepartment of Thoracic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People`s Republic of ChinaThe good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological response of PT and nodal downstaging using a pooled analysis to assess the effect of neoadjuvant immunotherapy on LNs. Original articles reporting the tumor major pathological response (ypT(MPR)), pathological complete response (ypT0) and nodal downstaging following neoadjuvant immunotherapy in NSCLC were retrieved. The OR and 95% CI were calculated by Review Manager V.5.3. Subgroup analysis was performed according to the neoadjuvant therapy regimen used. A total of 209 patients from 6 studies were included in this analysis. The frequency of nodal downstaging was comparable to that of ypT(MPR) (OR 1.31; 95% CI 0.84 to 2.05; p=0.24). Interestingly, ypN0 was observed more frequently than ypT0 (OR 3.26; 95% CI 2.06 to 5.16; p<0.0001). However, this difference was not observed in the subgroup of cN2 patients who underwent immune checkpoint inhibitor monotherapy (OR 1.58; 95% CI 0.56 to 4.48; p=0.39). Neoadjuvant immunotherapy results in satisfactory response in metastatic LN. Patients had a high probability of node clearance when ypT0 was confirmed, especially in patients treated with immunochemotherapy.https://jitc.bmj.com/content/10/9/e005160.full |
| spellingShingle | Hao Long Si Chen Hui Yu Wen-Yu Zhai Ze-Rui Zhao Yao-Bin Lin Yi-Zhi Wang Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis Journal for ImmunoTherapy of Cancer |
| title | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
| title_full | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
| title_fullStr | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
| title_full_unstemmed | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
| title_short | Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis |
| title_sort | response of primary tumor and lymph node in non small cell lung cancer after neoadjuvant immunotherapy a pooled analysis |
| url | https://jitc.bmj.com/content/10/9/e005160.full |
| work_keys_str_mv | AT haolong responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT sichen responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT huiyu responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT wenyuzhai responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT zeruizhao responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT yaobinlin responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis AT yizhiwang responseofprimarytumorandlymphnodeinnonsmallcelllungcancerafterneoadjuvantimmunotherapyapooledanalysis |